Advertisement

Rheumatology International

, Volume 30, Issue 11, pp 1437–1440 | Cite as

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

  • Anna Rita Giardina
  • Angelo Ferrante
  • Francesco Ciccia
  • Rosalia Impastato
  • Maria Concetta Miceli
  • Alfonso Principato
  • Giovanni Triolo
Original Article

Abstract

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated.

Keywords

Ankylosing spondylitis Etanercept Infliximab 

References

  1. 1.
    Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 135:896–907Google Scholar
  2. 2.
    Zochling J, van der Heijde D, Dougados M et al (2006) Current evidence for the management of ankylosing spondylitis: systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65:423–432CrossRefPubMedGoogle Scholar
  3. 3.
    Rudwaleit M, Hohler T (2001) Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr Opin Rheumatol 13:250–254CrossRefPubMedGoogle Scholar
  4. 4.
    Davis JC, van der Heijde DM, Braun J et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352CrossRefPubMedGoogle Scholar
  5. 5.
    Brandt J, Khariouzov A, Listing J, Haibel H et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667–1675CrossRefPubMedGoogle Scholar
  6. 6.
    Davis JC, van der Heijde DM, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 48:3230–3236CrossRefPubMedGoogle Scholar
  7. 7.
    Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600CrossRefPubMedGoogle Scholar
  8. 8.
    Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342–348CrossRefPubMedGoogle Scholar
  9. 9.
    Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193CrossRefPubMedGoogle Scholar
  10. 10.
    Braun J, Brandt J, Listing J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229–234CrossRefPubMedGoogle Scholar
  11. 11.
    van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 52:582–591CrossRefPubMedGoogle Scholar
  12. 12.
    Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575CrossRefPubMedGoogle Scholar
  13. 13.
    Braun J, Brandt J, Listing J et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224–2233CrossRefPubMedGoogle Scholar
  14. 14.
    Braun J, Landewé R, Hermann KGA et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652CrossRefPubMedGoogle Scholar
  15. 15.
    Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34:819–836CrossRefPubMedGoogle Scholar
  16. 16.
    Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368CrossRefPubMedGoogle Scholar
  17. 17.
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876–1886CrossRefPubMedGoogle Scholar
  18. 18.
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMedGoogle Scholar
  19. 19.
    Fernández-Sueiro JL, Willisch A, Pértega-Díaz S et al (2009) Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 61(3):386–392CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Anna Rita Giardina
    • 1
  • Angelo Ferrante
    • 1
  • Francesco Ciccia
    • 1
  • Rosalia Impastato
    • 1
  • Maria Concetta Miceli
    • 1
  • Alfonso Principato
    • 1
  • Giovanni Triolo
    • 1
  1. 1.Division of Rheumatology, Department of Internal MedicineUniversity of PalermoPalermoItaly

Personalised recommendations